Contact us — Biologic Eye Drops

Skip to Content

Report problems to the FDA

Report deceptive advertising

A Patient's Story

DrB's Educational Presentations

Non-Preserved Eye Drop Safety

The Placebo Effect

On Label, Off Label or No Label?

Placentas from Strangers

DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)

FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)

FDA Warning Letter to Neobiosis (June 5, 2024)

FDA Inspection Form 483 - RPP Tampa (June 23, 2023)

FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)

DEF Open Letter to the FDA (May 12, 2023)

DEF Open Letter to the Eye Care Press (May 5, 2023)

DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)

FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)

DEF Open Letter re StimulEyes (Mar 9, 2023)

DEF Open Letter to Regener-Eyes (Mar 5, 2023)

FDA Untitled Letter re StimulEyes (Nov 17, 2022)

FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)

DEF Open Letter to Regener-Eyes (Sep 29, 2022)

DEF Regulatory Compliance Summary Information (June 8, 2022)

DEF Open letter for Eye Care Professionals (May 16, 2022)

Report problems to the FDA

Report deceptive advertising

A Patient's Story

DrB's Educational Presentations

Non-Preserved Eye Drop Safety

The Placebo Effect

On Label, Off Label or No Label?

Placentas from Strangers

DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)

FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)

FDA Warning Letter to Neobiosis (June 5, 2024)

FDA Inspection Form 483 - RPP Tampa (June 23, 2023)

FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)

DEF Open Letter to the FDA (May 12, 2023)

DEF Open Letter to the Eye Care Press (May 5, 2023)

DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)

FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)

DEF Open Letter re StimulEyes (Mar 9, 2023)

DEF Open Letter to Regener-Eyes (Mar 5, 2023)

FDA Untitled Letter re StimulEyes (Nov 17, 2022)

FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)

DEF Open Letter to Regener-Eyes (Sep 29, 2022)

DEF Regulatory Compliance Summary Information (June 8, 2022)

DEF Open letter for Eye Care Professionals (May 16, 2022)

Report problems to the FDA

Report deceptive advertising

Folder: Watch & Learn

A Patient's Story

DrB's Educational Presentations

Non-Preserved Eye Drop Safety

The Placebo Effect

On Label, Off Label or No Label?

Placentas from Strangers

Folder: History

DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)

FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)

FDA Warning Letter to Neobiosis (June 5, 2024)

FDA Inspection Form 483 - RPP Tampa (June 23, 2023)

FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)

DEF Open Letter to the FDA (May 12, 2023)

DEF Open Letter to the Eye Care Press (May 5, 2023)

DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)

FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)

DEF Open Letter re StimulEyes (Mar 9, 2023)

DEF Open Letter to Regener-Eyes (Mar 5, 2023)

FDA Untitled Letter re StimulEyes (Nov 17, 2022)

FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)

DEF Open Letter to Regener-Eyes (Sep 29, 2022)

DEF Regulatory Compliance Summary Information (June 8, 2022)

DEF Open letter for Eye Care Professionals (May 16, 2022)

Contact us

info@dryeyefoundation.org
(800) 484-0244

The Dry Eye Foundation
26287 Twelve Trees Lane NW
Poulsbo, WA 98370

Join mailing list(s)

Join Dry Eye Foundation mailing list(s)

Copyright © 2026. All rights reserved.